Circular RNAs Serve as Prognostic, Diagnostic and Clinicopathological Markers in Lung Cancer: An Updated Systematic Review and Meta-Analysis

Zhuozheng Liang
Third Affiliated Hospital of Sun Yat-Sen University

Cui Chen
Guangdong Medical University

Cheng Guo
Third Affiliated Hospital of Sun Yat-Sen University Department of Otorhinolaryngology Head and Neck Surgery

Ping Meng
Third Affiliated Hospital of Sun Yat-Sen University

Manman Zou
Third Affiliated Hospital of Sun Yat-Sen University

Liyi Zhang
Third Affiliated Hospital of Sun Yat-Sen University

Hui Liu
Third Affiliated Hospital of Sun Yat-Sen University

Tiantuo Zhang (hitcinmatalzz@163.com)
Third Affiliated Hospital of Sun Yat-Sen University

Research article

Keywords: Lung cancer, Circular RNA, Diagnosis, Prognosis, Meta-analysis

DOI: https://doi.org/10.21203/rs.2.24261/v2

License: Creative Commons Attribution 4.0 International License. Read Full License
Abstract

**Background:** In recent years, the roles of circular RNAs (circRNAs) in the biogenesis and clinical application have gradually garnered much interest in the field of cancer research. However, high-quality studies evaluating the roles of circRNAs in clinicopathological features and clinical application of lung cancer are still unrevealed. Herein, we aimed to elucidate the functions of circRNAs in the association with clinicopathology, diagnosis and prognosis in lung cancer.

**Methods:** Comprehensive and reasonable search strategies were used in four databases up to Nov. 24th, 2019. The odds ratio (OR) was used to analyze the risks of circRNAs in lung cancer. Sensitivity (Sen), specificity (Spe) and area under curve (AUC) were used to assess the diagnostic value. What's more, the hazard ratio (HR) was used for the analysis of survival outcomes. A fixed-effect model was firstly used in data analysis. If $I^2 >50\%$ in heterogeneity, the random-effect model was chosen.

**Results:** A total of 50 studies with 3815 samples were incorporated into our meta-analysis, in which 40 focused on clinical characteristics, 10 related to diagnosis and 31 were aimed at prognosis. In terms of clinical characteristics, both OR and 95% confidence interval (95%CI) were shown that circRNAs were significantly associated with TNM, tumor differentiation, lymph node metastasis, distal metastasis and tumor size in lung cancer. For diagnosis, both upregulated and downregulated circRNAs distinguished patients with lung cancer from healthy people with pooled Sen, Spe and AUC, of which the values were 0.78, 0.76 and 0.81 respectively. In the section of prognosis, circRNAs can better predict the survival time of patients with lung cancer (overall survival, OS: \( HR=0.46, 95\% CI: 0.33–0.65 \) in downregulated circRNAs; \( HR=2.23, 95\% CI: 1.97-2.53 \) in upregulated circRNAs).

**Conclusions:** The results presented here suggested that circRNAs were the potential cancer biomarkers in clinicopathology, diagnosis and prognosis of lung cancer patients, which deserve further application in clinical practice.

**Background**

According to global cancer statistics in 2018, lung cancer has become the leading cause of cancer morbidity and mortality, with 11.6% of all new diagnosis cancer cases and 18.4% of total cancer death cases[1]. Lung cancer is composed of non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), of which NSCLC accounts for nearly 85%. Complete surgical resection is the most effective and available treatment in the early-stage of lung cancer. Notably, 5-year survival rates of lung cancer will decrease by 45% in stage III, compared with stage I of lung cancer[2]. However, due to a lack of accurate and sensitive screening methods to detect early-stage lung cancer, it was estimated that 7 out of 10 patients died after the diagnosis of lung cancer in the United States[3]. Hence, it is urgent to seek and develop brand-new biomarkers to improve the status.

Circular RNA (circRNA), a loop structure with a 3'-5' covalently closed link, is a novel molecule for tumorigenesis and tumor development[3]. Since the absence of 5'-cap structure and 3'-poly(A) tail,
circRNAs are stable and kept from exonucleases[4]. Characterized by master regulatory function, circRNAs has become the focus of attention in the research of lung cancer. In recent years, researches on circRNAs on oncogenesis, metastasis, diagnosis and prognosis have been extensively performed in various cancer types, especially in lung cancer. Xin Huang et al. pooled a total of 23 studies to assess the relationship between circRNAs and lung cancer in terms of clinicopathological features, prognosis and diagnosis[5]. However, the results showed in their study were lack of convincing due to limited included researches.

Although a growing body of studies suggested that circRNAs play a key role in lung cancer in the fields of diagnosis, prognosis and treatment, a high-quality study with reliable pooled results is still absent. Therefore, our study shed highlight on investigating and assessing the diagnostic and prognostic roles of circRNAs in lung cancer. What’s more, the relationship between clinicopathological features in lung cancer and circRNAs was also thoroughly evaluated in this study.

**Methods**

**Search strategy**

The searching work was performed in four main databases, including PubMed, PubMed Central (PMC), Embase and Web of Science, up to Nov. 24th, 2019, with a search strategy combining terms: ("circRNA" or "circular RNA") and ("lung cancer" or "lung neoplasm" or "lung carcinoma" or "lung tumor") in Title/Abstract and Subject heading. The references of the final searched studies were initially processed examination by title and abstract, and then potential eligible studies were further looked for full-text articles when necessary. It is indispensable for two researchers (Liang and Guo) to independently carry out this part.

**Data inclusion and exclusion**

Studies included in our work must meet the following criteria:

- Studies focused on the relationship between certain circRNA and lung cancer and data included clinicopathology, diagnosis or prognosis;
- The total number of the sample (including lung tumor tissue and paired adjacent non-tumorous tissue), Sen, Spe, AUC, HR and follow-up time were available;
- Case-control or cohort.
- Researches on circRNA in all kinds of specimens in patients suffering from lung cancer using qRT-PCR were included.

Exclusion can be performed at the following criteria:

- Meta-analysis, review, case report or only abstract;
- The article was not written in English;
No available data can be extracted in clinical parameters, diagnosis or prognosis;
Animal researches or cancer cell experiments.

**Data extraction**

The extracted information was obtained in each eligible study by two independent researchers. To rule out discrepancy and obtain consistent data, extracted information was then cross-checked between the two researchers. Disagreement was solved by consulting with a third researcher (Chen). All collected studies were extracted the following data: first author, publication year, circRNAs, the expression level of circRNA (upregulated or downregulated) and cancer types. For clinicopathological features, the extraction of age, gender, smoking, histological type, tumor size, distal metastasis, lymph node metastasis, differentiation and TNM stage were available. For the part of the diagnosis, the samples of case and control, sample types and diagnostic value, including sensitivity, specificity and AUC were available collected. As for the assessment of prognosis, case number classified by expression level, HR and 95%CI, following-up period, and overall survival (OS) were available obtained. Notably, some of the eligible articles missed the important values (HR and 95%CI), but these values could be calculated by Engauge Digitizer Software (version 11.1). The quality of the articles was examined by the Newcastle-Ottawa scale (NOS, Supplementary Table 1). The articles with scores ≥ 7 were identified as high quality.

**Statistically analysis**

Stata, V14.0 software was utilized to analyze in our meta-analysis to combine Sen, Spe, AUC, HR and OR value. OR and 95%CI were used to assess clinicopathological features, and sensitivity, specificity and AUC were used to assess the effect of diagnosis. What’s more, HR and 95%CI were needed to determine the prediction of prognosis. Q-test and I²-test were used to determine the heterogeneity between studies. A fixed-effects model was applied for the analysis if I²<50%. The random-effects model would be used otherwise. If P<0.1 in the Q-test or I²>50%, sensitivity analysis and subgroup analysis would be performed to further analyze the potential source of heterogeneity. Both Begg’s test and Egger’s test were used to quantitatively confirm whether publication bias existed. P<0.05 in both results indicated that there was no publication bias in the analysis.

**Results**

**Search results**

Referencing comprehensive and appropriate search strategies, the flow chart showed the steps related to screening the studies for the meta-analysis (Figure 1). A total of 479 eligible articles were selected from four main databases up to Nov. 24th, 2019. In these articles, 429 records were eliminated, including 232 records for duplicates, 161 records excluded after screening for title and abstract, and 36 studies were got rid of our meta-analysis because of the following reasons: no full-text articles, review or meta-analysis, insufficient data and not related to circRNAs or lung cancer. Finally, 50 full-text articles with a total of
3815 samples acceded to our meta-analysis, including 39 tumor promoters and 15 tumor suppressors. These studies illuminated the correlation between circRNAs and clinical characteristics, diagnosis and prognosis respectively.

**Clinical pathology**

40 studies with 32 tumor promoters and 8 tumor suppressors included in this part were shown in **Supplementary Table 2-10**. The association between circRNAs expression and clinical characteristics of lung cancer patients was presented in the summary table (**Table 1**). The results indicated that oncogenic circRNAs were remarkably associated with later TMN stage \((OR = 2.74, 95\% \text{ CI: }1.81–4.15)\), poor differentiation \((OR = 2.22, 95\% \text{ CI: }1.73–2.85)\), higher rate of lymph node metastasis \((OR = 1.92, 95\% \text{ CI: }1.27–2.90)\) , higher rate of distal metastasis \((OR = 2.86, 95\% \text{ CI: }1.29–6.30)\) and larger tumor size \((OR = 1.72, 95\% \text{ CI: }1.08–2.46)\). Oddly enough, upregulated circRNAs had no statistical relationship to TMN stage when compared stage II-VI with stage I. The \(P\)-value was greater than 0.05 in subgroups analysis of various tumor size. Moreover, the higher expression of downregulated circRNAs was associated with earlier TMN stage \((OR = 0.41, 95\% \text{ CI: }0.21–0.80)\), lower rate of lymph node metastasis \((OR = 0.32, 95\% \text{ CI: }0.17–0.61)\), and smaller tumor size \((OR = 0.50, 95\% \text{ CI: }0.27–0.94)\). Whereas, neither tumor promoters nor suppressors mentioned above were correlated with patients’ age, gender, smoking and histological type.

**Diagnostic analysis of circRNAs**

Our meta-analysis presented the pooled results of 10 upregulated and 6 downregulated circRNAs in 10 studies for diagnosis in lung cancer (**Table 2**). This study estimated some indexes as follows: sensitivity (Sen), 0.78 (0.75–0.80); specificity (Spe), 0.76 (0.71–0.79) (**Supplementary Figure 1**); positive likelihood ratio (PLR), 3.20 (2.70–3.80); negative likelihood ratio (NLR), 0.30 (0.25–0.34); and diagnostic odds ratio (DOR), 11.0 (8.0–14.0) (data not shown), respectively. The heterogeneity \((I^2)\) of overall sensitivity and specificity were 19.8% and 47.6%, respectively. Additionally, we drew a summary receiver operator characteristic (SROC) curve for circRNAs and calculated the value of 0.81 AUC (**Figure 2A**). Fagan’s nomogram and likelihood ratio diagram were used to estimate the clinical value of circRNAs’ diagnosis. Fagan’s diagram presented that the positive probability of precisely diagnosing lung cancer was 76% at the high expression of oncogenic circRNAs or low expression of anti-tumor circRNAs, while the negative probability was only 23% at the normal expression of upregulated and downregulated circRNAs (**Figure 2B**). As we can see in **Figure 2C**, nearly all circRNAs located in lower right quadrants, which means no exclusion or confirmation value of circRNAs in lung cancer. To find out the between-study heterogeneity, subgroup analysis and sensitivity analysis were performed to uncover the source of heterogeneity. The subgroup analysis revealed that only the specificity of upregulated circRNAs had remarkable heterogeneity (**Figure 3**). The sensitivity analysis illustrated that the stability of results by omitting studies one by one and construed the source of heterogeneity (**Supplementary Figure 2**). The results of sensitivity
analysis revealed that the heterogeneity was mainly derived from the study of Xiaoli Zhu (hsa_circ_0013958 in plasma) and the study of Liang Zong (hsa_circ_102231 in tissue). Although the heterogeneity of sensitivity and especially specificity was overwhelmingly decreased after omitting the above studies one by one, the diagnostic value almost stayed unchanged (Supplementary Figure 3). Furthermore, the funnel plot revealed that publication bias might exist in studies (Supplementary Figure 4) and the results were further quantificationally confirmed by Begg's test ($Z=3.38$, $P=0.001$) and Egger's test ($t=3.85$, $P=0.002$).

**Prognostic analysis of circRNAs**

31 included studies with 26 upregulated circRNAs and 5 downregulated circRNAs were summarized in Table 3. The figure showed that high expression of oncogenic circRNAs significantly related to poor prognosis (OS: $HR = 2.23$, 95%CI: 1.97–2.53), and the elevation of anti-tumor circRNAs was associated with longer overall survival (OS: $HR = 0.46$, 95%CI: 0.33–0.65) (Figure 4). Neither tumor promoters nor tumor suppressors could be found heterogeneity between studies ($I^2 = 0.0\%$). No evidence of publication bias for prognosis was found from Begg's test (upregulated circRNAs: $P=0.134$; downregulated circRNAs: $P=0.462$) and Egger's test (upregulated circRNAs: $P=0.095$; downregulated circRNAs: $P=0.434$).

**Discussion**

The present study mainly focused on investigating the potential clinical role of circRNAs in lung cancer in terms of clinical characteristics, diagnosis and prognosis. Our results could be obtained from a total of 50 articles involving 3815 samples (lung tumor tissues and paired adjacent non-tumor tissues). The previous meta-analysis reported by Xin Huang et al. revealed that the diagnostic value of circRNAs in lung cancer was 0.86 AUC, with 77% sensitivity and 81% specificity. Moreover, they also reported that patients with increased expression of oncogenic circRNAs had poor survival (OS: $HR=3.24$), while patients with elevated anti-tumor circRNAs had longer survival (OS: $HR=0.57$)[5]. However, the results of the present work were different from the previous study. For diagnosis, although the sensitivity of 78% had a little increase, both AUC and specificity were decreased by 5%. A conclusion that circRNAs might not accurately confirm or exclude lung cancer could be drawn from Fagan’s diagram and likelihood ratio diagram. To sum up, the current circRNAs had limited clinical diagnostic value. It turned out that the combination with two or more circRNAs rather than a single might improve overall diagnostic value.

As for prognosis, increased oncogenic circRNAs had more than a two-fold increased risk with poor survival. At the same time, elevated anti-tumor circRNAs had a two-fold decreased risk with unfavorable survival. Our results showed that both upregulated and downregulated circRNAs could be identified as good predictors of prognosis. When it comes to clinical features, something interesting was found in subgroup analysis. Although TNM stages, differentiation of tumor and tumor size were remarkably related to upregulated circRNAs, when compared stage II-IV with stage I in TNM, there was no significant relationship between circRNAs (both tumor promoter and suppressor) and TNM stages. These might be
explained that circRNAs were not sensitively expressed in the early-stage of lung cancer, including stage I and stage II. On the whole, compared with the study of Xin Huang, we newly discovered there were significant associations between downregulated circRNAs and differentiation, lymph node metastasis and tumor size. Moreover, we included patients with distal metastasis in our research and concluded that the expression of upregulated circRNAs was positively correlated with more distal metastasis.

The current study still had some deficiencies. The sample limitation of diagnosis analysis was existing. Only 10 studies with 16 circRNAs were pooled in our study, which would lead to unstable results of the diagnosis. In addition, due to insufficient studies of investigating plasma and serum samples, subgroup analysis could not be performed to analyze the diagnostic value of different samples.

In short, although the investigation of circRNAs has made a great stride in recent years, the diagnostic value of circRNAs is still limited. To summarize, circRNAs were good predictors of prognosis in lung cancer, and effective indicators of many clinical parameters, such as TNM stages, differentiation, lymph node metastasis, tumor size and distal metastasis.

**Conclusion**

It is possible that the circRNAs can be served as prognostic biomarkers and great predictors of clinical pathology for lung cancer. However, it seems that a single circRNA is not suitable as a good diagnostic biomarker for lung cancer. Therefore, future investigation should be required to develop diagnostic value of the combination of two or more circRNAs.

**Declarations**

**Ethics approval and consent to participate**

Not applicable.

**Consent for publication**

Not applicable.

**Availability of data and materials**

Not applicable.

**Competing interests**

The authors declare that they have no competing interests.

**Funding**

This work was supported by the National Natural Science Foundation of China No. 81472760.
Author Contributions

Z-ZL and CG contributed to the conception and design of this work. Z-ZL, CG and CC were responsible for the acquisition and analysis of the data. PM and M-MZ wrote parts of the manuscript. L-YZ, HL and T-TZ checked the data and revised the manuscript. All authors have read and approved the manuscript.

Acknowledgements

Not applicable.

Abbreviations

circular RNAs, circRNAs; odds ratio, OR; 95% confidence interval, 95% CI; sensitivity, Sen; specificity, Spe; area under curve, AUC; non-small cell lung cancer, NSCLC; small cell lung cancer, SCLC; overall survival, OS; positive likelihood ratio, PLR; negative likelihood ratio, NLR; diagnostic odds ratio, DOR; summary receiver operator characteristic, SROC; LSCC, lung squamous cell carcinoma; LAC, lung adenocarcinoma; LC, lung cancer.

References

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018, 68(6):394-424.
2. Vielva LR, Jaen MW, Alcacer JA, Cardona MC: State of the art in surgery for early stage NSCLC-does the number of resected lymph nodes matter? Transl Lung Cancer Res 2014, 3(2):95-99.
3. GOEBEL C, LOUDEN CL, MCKENNA R, ONUGHA O, WACHTEL A, LONG T: Diagnosis of Non-small Cell Lung Cancer for Early Stage Asymptomatic Patients. Cancer Genomics - Proteomics 2019, 16(4):229-244.
4. Zhang Y, Xue W, Li X, Zhang J, Chen S, Zhang J, Yang L, Chen L: The Biogenesis of Nascent Circular RNAs. CELL REP 2016, 15(3):611-624.
5. Huang X, Zhang W, Shao Z: Prognostic and diagnostic significance of circRNAs expression in lung cancer. J CELL PHYSIOL 2019, 234(10):18459-18465.
6. Liu XX, Yang YE, Liu X, Zhang MY, Li R, Yin YH, Qu YQ: A two-circular RNA signature as a noninvasive diagnostic biomarker for lung adenocarcinoma. J TRANSL MED 2019, 17(1):10-1186.
7. Chen LJ, Nan A, Zhang N, Jia YY, Li X, Ling YH, Dai JB, Zhang SZ, Yang QY, Yi YN et al: Circular RNA 100146 functions as an oncogene through direct binding to miR-361-3p and miR-615-5p in non-small cell lung cancer. MOL CANCER 2019, 18(13):10-1186.
8. Li JP, Wang JH, Chen Z, Chen Y, Jin MW: Hsa_circ_0079530 promotes cell proliferation and invasion in non-small cell lung cancer. GENE 2018, 665:1-5.
9. Zong L, Sun QC, Zhang HP, Chen ZX, Deng YC, Li DS, Zhang LW: Increased expression of circRNA_102231 in lung cancer and its clinical significance. BIOMED PHARMACOTHER 2018, 102:639-644.

10. Zhang SY, Zeng XL, Ding T, Guo L, Li YL, Ou SL, Yuan H: Microarray profile of circular RNAs identifies hsa_circ_0014130 as a new circular RNA biomarker in non-small cell lung cancer. SCI REP-UK 2018, 8:10-1038.

11. Li XY, Zhang ZL, Jiang H, Li Q, Wang RL, Pan HL, Niu YY, Liu FH, Gu HM, Fan XJ et al: Circular RNA circPVT1 Promotes Proliferation and Invasion Through Sponging miR-125b and Activating E2F2 Signaling in Non-Small Cell Lung Cancer. CELL PHYSIOL BIOCHEM 2018, 51(5):2324-2340.

12. Zhu XL, Wang XY, Wei SZ, Chen Y, Chen Y, Fan XB, Han SH, Wu GQ: hsa_circ_0013958: a circular RNA and potential novel biomarker for lung adenocarcinoma. FEBS J 2017, 284(14):2170-2182.

13. Fan CM, Wang JP, Tang YY, Zhao J, He SY, Xiong F, Guo C, Xiang B, Zhou M, Li XL et al: circMAN1A2 may serve as a novel serum biomarker for malignant tumors. CANCER SCI 2019, 00:1-9.

14. Zhang YN, Zhao H, Zhang LC: Identification of the tumor-suppressive function of circular RNA FOXO3 in non-small cell lung cancer through sponging miR-155. MOL MED REP 2018, 17(6):7692-7700.

15. Xu F, Liu Y, Dai Y, Li CS, Li CS, Chang Y, Ma YF, Li YJ, Chen LA: Clinical correlation and diagnostic value of circular RNA determined via next-generation sequencing in lung squamous cell carcinomas. INT J CLIN EXP MED 2018, 11(11):11706.

16. Han JQ, Zhao GB, Ma X, Dong Q, Zhang H, Wang Y, Cui J: CircRNA circ-BANP-mediated miR-503/LARP1 signaling contributes to lung cancer progression. BIOCHEM BIOPH RES CO 2018, 503(4):2429-2435.

17. Qiu MT, Xia WJ, Chen R, Wang SW, Xu YT, Ma ZF, Xu WZ, Zhang EB, Wang J, Fang T et al: The Circular RNA circPRKCI Promotes Tumor Growth in Lung Adenocarcinoma. CANCER RES 2018, 78(11):2839-2851.

18. Yao YS, Hua QW, Zhou YJ, Shen HB: CircRNA has_circ_0001946 promotes cell growth in lung adenocarcinoma by regulating miR-135a-5p/SIRT1 axis and activating Wnt/beta-catenin signaling pathway. BIOMED PHARMACOTHER 2019, 111:1367-1375.

19. Qiu BQ, Zhang PF, Xiong D, Xu JJ, Long X, Zhu SQ, Ye XD, Wu Y, Pei X, Zhang XM et al: CircRNA fibroblast growth factor receptor 3 promotes tumor progression in non-small cell lung cancer by regulating Galectin-1-AKT/ERK1/2 signaling. J CELL PHYSIOL 2019, 234(7):11256-11264.

20. Wang LX, Ma HP, Kong WX, Liu B, Zhang XQ: Up-regulated circular RNA VANGL1 contributes to progression of non-small cell lung cancer through inhibition of miR-195 and activation of Bcl-2. BIOSCIENCE REP 2019, 39(6):10-1042.

21. Huang Q, Wang SD, Li X, Yang F, Feng CJ, Zhong KZ, Qiu MT, Wang J: Circular RNA ATXN7 is upregulated in non-small cell lung cancer and promotes disease progression. ONCOL LETT 2019, 17(6):4803-4810.
22. Liu GH, Shi HB, Deng LL, Zheng HY, Kong WL, Wen XQ, Bi HX: Circular RNA circ-FOXM1 facilitates cell progression as ceRNA to target PPDPF and MACC1 by sponging miR-1304-5p in non-small cell lung cancer. *BIOCHEM BIOPH RES CO* 2019, 513(1):207-212.

23. An JC, Shi HB, Zhang N, Song SQ: Elevation of circular RNA circ_0003645 forecasts unfavorable prognosis and facilitates cell progression via miR-1179/TMEM14A pathway in non-small cell lung cancer. *BIOCHEM BIOPH RES CO* 2019, 511(4):921-925.

24. Han W, Wang LF, Zhang LH, Wang YY, Li Y: Circular RNA circ-RAD23B promotes cell growth and invasion by miR-593-3p/CCND2 and miR-653-5p/MIAM1 pathways in non-small cell lung cancer. *BIOCHEM BIOPH RES CO* 2019, 510(3):462-466.

25. Qin S, Zhao Y, Lim G, Lin H, Zhang X, Zhang X: Circular RNA PVT1 acts as a competing endogenous RNA for miR-497 in promoting non-small cell lung cancer progression. *BIOMED PHARMACOTHER* 2018, 111:244-250.

26. Zhou Y, Zheng X, Xu B, Chen LJ, Wang Q, Deng HF, Jiang JT: Circular RNA hsa_circ_0004015 regulates the proliferation, invasion, and TKI drug resistance of non-small cell lung cancer by miR-1183/PDPK1 signaling pathway. *BIOCHEM BIOPH RES CO* 2019, 508(2):527-535.

27. Yan B, Zhang W, Mao XW, Jiang LY: Circular RNA ciRS-7 correlates with advance disease and poor prognosis, and its down-regulation inhibits cell proliferation while inducing cells apoptosis in non-small cell lung cancer. *EUR REV MED PHARMACO* 2018, 22(24):8712-8721.

28. Zou QG, Wang TJ, Li B, Li GH, Zhang LX, Wang B, Sun SL: Overexpression of circ-0067934 is associated with increased cellular proliferation and the prognosis of non-small cell lung cancer. *ONCOL LETT* 2018, 16(5):5551-5556.

29. Qi Y, Zhang BQ, Wang JT, Yao MN: Upregulation of circular RNA hsa_circ_0007534 predicts unfavorable prognosis for NSCLC and exerts oncogenic properties in vitro and in vivo. *GENE* 2018, 676:79-85.

30. Zhao FC, Han YR, Liu ZZ, Zhao ZX, Li ZR, Jia K: circFADS2 regulates lung cancer cells proliferation and invasion via acting as a sponge of miR-498. *BIOSCIENCE REP* 2018, 38(4):10-1042.

31. Li YS, Hu JH, Li LJ, Cai SY, Zhang HC, Zhu XF, Guan GJ, Dong XM: Upregulated circular RNA circ_0016760 indicates unfavorable prognosis in NSCLC and promotes cell progression through miR-1287/GAGE1 axis. *BIOCHEM BIOPH RES CO* 2018, 503(3):2089-2094.

32. Liu W, Ma WM, Yuan Y, Zhang YW, Sun SY: Circular RNA hsa_circRNA_103809 promotes lung cancer progression via facilitating ZNF121-dependent MYC expression by sequestering miR-4302. *BIOCHEM BIOPH RES CO* 2018, 500(4):846-851.

33. Su CY, Han Y, Zhang HT, Li YS, Yi L, Wang XJ, Zhou SJ, Yu DP, Song XY, Xiao N et al: CiRS-7 targeting miR-7 modulates the progression of non-small cell lung cancer in a manner dependent on NF-kappa B signalling. *J CELL MOL MED* 2018, 22(6):3097-3107.

34. Wang J, Li H: CircRNA circ_0067934 silencing inhibits the proliferation, migration and invasion of NSCLC cells and correlates with unfavorable prognosis in NSCLC. *EUR REV MED PHARMACO* 2018, 22(10):3053-3060.
35. Qu DH, Yan BD, Xin R, Ma TG: A novel circular RNA hsa_circ_0020123 exerts oncogenic properties through suppression of miR-144 in non-small cell lung cancer. *AM J CANCER RES* 2018, 8(8):1387-1402.

36. Zhang XF, Yang DF, Wei YQ: Overexpressed CDR1 as functions as an oncogene to promote the tumor progression via miR-7 in non-small-cell lung cancer. *ONCOTARGETS THER* 2018, 11:3979-3987.

37. Wan J, Hao L, Zheng X, Li Z: Circular RNA circ_0020123 promotes non-small cell lung cancer progression by acting as a ceRNA for miR-488–3p to regulate ADAM9 expression. *BIOCHEM BIOPH RES CO* 2019, 515(2):303-309.

38. Li XY, Liu YR, Zhou JH, Li W, Guo HH, Ma HP: Enhanced expression of circular RNA hsa_circ_000984 promotes cells proliferation and metastasis in non-small cell lung cancer by modulating Wnt/beta-catenin pathway. *EUR REV MED PHARMACO* 2019, 23(8):3366-3374.

39. Ding LC, Yao WD, Lu JG, Gong J, Zhang XD: Upregulation of circ_001569 predicts poor prognosis and promotes cell proliferation in non-small cell lung cancer by regulating the Wnt/beta-catenin pathway. *ONCOL LETT* 2018, 16(1):453-458.

40. Chen X, Mao R, Su W, Yang X, Geng Q, Guo C, Wang Z, Wang J, Kresty LA, Beer DG et al: Circular RNA circHIPK3 modulates autophagy via MIR124-3p-STAT3-PRKAA/AMPKα signaling in STK11 mutant lung cancer. *AUTOPHAGY* 2019, DOI: 10.1080/15548627.2019.1634945.

41. Yang L, Wang J, Fan YD, Yu K, Jiao BW, Su XS: Hsa_circ_0046264 up-regulated BRCA2 to suppress lung cancer through targeting hsa-miR-1245. *RESP RES* 2018, 19(115):10-1186.

42. Chen DS, Ma W, Ke ZY, Xie F: CircRNA hsa_circ_100395 regulates miR-1228/TCF21 pathway to inhibit lung cancer progression. *CELL CYCLE* 2018, 17(16):2080-2090.

43. Yao YS, Hua QW, Zhou YJ: CircRNA has_circ_0006427 suppresses the progression of lung adenocarcinoma by regulating miR-6783-3p/DKK1 axis and inactivating Wnt/beta-catenin signaling pathway. *BIOCHEM BIOPH RES CO* 2019, 508(1):37-45.

44. Zhang BB, Chen ML, Jiang N, Shi KF, Qian RL: A regulatory circuit of circ-MTO1/miR-17/QKI-5 inhibits the proliferation of lung adenocarcinoma. *CANCER BIOL THER*.

45. Liu TM, Song Z, Gai YL: Circular RNA circ_0001649 acts as a prognostic biomarker and inhibits NSCLC progression via sponging miR-331-3p and miR-338-5p. *BIOCHEM BIOPH RES CO* 2018, 503(3):1503-1509.

**Tables**

**Figures**
Table 1. The summary of clinicopathological features of circRNAs in lung cancer.

| Clinical characteristics | Tumor promoter | Tumor suppressor |
|--------------------------|----------------|-----------------|
|                          | OR  | 95%CI | P-value | OR  | 95%CI | P-value |
| TNM                      | 2.74 | 1.81-4.15 | <0.001 | 0.41 | 0.21-0.80 | 0.009 |
| III-IV vs I-II           | 2.90 | 1.90-4.42 | <0.001 | 0.32 | 0.18-0.59 | <0.001 |
| II-IV vs I               | 1.71 | 0.26-11.38 | 0.580 | 1.12 | 0.53-2.38 | 0.762 |
| Differentiation          | 2.22 | 1.73-2.85 | <0.001 | 1.82 | 1.05-3.15 | 0.032 |
| Modulate/ poor vs high   | 2.32 | 1.77-3.04 | <0.001 | 1.39 | 0.60-3.21 | 0.436 |
| Poor vs high/modulate    | 1.77 | 0.95-3.32 | 0.073 | 2.23 | 1.08-4.64 | 0.031 |
| Lymph node metastasis    | 1.92 | 1.27-2.90 | 0.002 | 0.32 | 0.17-0.61 | 0.001 |
| Distal metastasis (M1 vs M0) | 2.86 | 1.29-6.30 | 0.009 | 0.89 | 0.30-2.59 | 0.826 |
| Tumor size               | 1.72 | 1.08-2.46 | 0.022 | 0.50 | 0.27-0.94 | 0.032 |
| Age                      | 1.40 | 0.65-2.99 | 0.391 | — | — | — |
| Age                      | 1.51 | 0.86-2.64 | 0.154 | 0.40 | 0.14-1.13 | 0.083 |
| Age                      | 2.27 | 0.92-5.62 | 0.076 | 0.66 | 0.34-1.27 | 0.217 |
| Age                      | 0.84 | 0.69-1.03 | 0.095 | 0.77 | 0.54-1.10 | 0.157 |
| Age                      | 0.70 | 0.42-1.15 | 0.160 | — | — | — |
| Gender                   | 0.94 | 0.78-1.12 | 0.474 | 0.94 | 0.62-1.42 | 0.760 |
| Smoking                  | 1.03 | 0.81-1.30 | 0.836 | 1.17 | 0.60-2.30 | 0.641 |
| Histological             | 1.12 | 0.85-1.49 | 0.424 | 0.73 | 0.40-1.31 | 0.287 |
Figure 1

The flowchart showed the algorithm on how to perform the exclusion and inclusion of the eligible studies in our meta-analysis.
| Study               | Year | CircRNA         | Cancer Type | Sample | Regul. | Sample Type | Diagnosis power |
|---------------------|------|-----------------|-------------|--------|--------|-------------|-----------------|
| Xiaoxia Liu [6]     | 2019 | hsa_circ_0005962 | LAC         | 153    | 54     | Plasma      | 0.72 0.72 0.73  |
| Lijian Chen [7]     | 2019 | hsa_circ_100146 | NSCLC       | 40     | 40     | Tissue      | 0.76 0.58 0.64  |
| Jipeng Li [8]       | 2018 | hsa_circ_0079530 | NSCLC       | 92     | 92     | Tissue      | 0.76 0.72 0.76  |
| Liang Zong [9]      | 2018 | hsa_circ_102231 | LAC         | 57     | 57     | Tissue      | 0.81 0.89 0.90  |
| Shaoyan Zhang [10]  | 2018 | hsa_circ_0014130 | NSCLC       | 46     | 46     | Tissue      | 0.87 0.85 0.88  |
| Xiuyan Li [11]      | 2018 | circ-PVT1       | NSCLC       | 45     | 45     | Tissue      | 0.83 0.68 0.80  |
| Xiuyan Li [11]      | 2018 | circ-PVT1       | NSCLC       | 45     | 45     | Serum       | 0.71 0.80 0.79  |
| Xiaoli Zhu [12]     | 2017 | hsa_circ_0013958 | LAC         | 49     | 49     | Tissue      | 0.76 0.80 0.82  |
| Xiaoli Zhu [12]     | 2017 | hsa_circ_0013958 | LAC         | 30     | 30     | Plasma      | 0.67 0.93 0.80  |
| Chunmei Fan [13]    | 2019 | circ-MAN1A2     | LC          | 45     | 121    | Serum       | 0.51 0.79 0.65  |
| Authors | Year | CircRNA ID | Tumor Type | Tissue Type | Expression Direction | Tissue Type | SEN | SPE | AUC |
|---------|------|------------|-------------|-------------|----------------------|-------------|-----|-----|-----|
| Xiaoxia Liu | 2019 | hsa_circ_0086414 | LAC | Plasma | Down | 153 | 54 | 0.77 | 0.67 | 0.78 |
| Yanni Zhang | 2018 | circ-FOXO3 | NSCLC | Tissue | Down | 45 | 45 | 0.8 | 0.73 | 0.78 |
| Fei Xu | 2018 | hsa_circ_0072309 | LSCC | Tissue | Down | 43 | 43 | 0.88 | 0.74 | 0.87 |
| Fei Xu | 2018 | hsa_circ_0006114 | LSCC | Tissue | Down | 43 | 43 | 0.86 | 0.72 | 0.82 |
| Fei Xu | 2018 | hsa_circ_0006460 | LSCC | Tissue | Down | 43 | 43 | 0.81 | 0.70 | 0.78 |
| Fei Xu | 2018 | hsa_circ_0077837 | LSCC | Tissue | Down | 43 | 43 | 0.86 | 0.81 | 0.86 |

Note: NSCLC, non-small cell lung cancer; LC, lung cancer; LAC, lung adenocarcinoma; LSCC, lung squamous cell carcinoma; SEN, sensitivity; SPE, specificity, AUC, area under curve.
Table 3. The summary of included circRNAs in lung cancer for prognosis.

| Author/Year | circRNA   | Up Down | Cancer type | Expression | HR (95% CI) | Follow-up (months) |
|-------------|-----------|---------|-------------|------------|-------------|-------------------|
| Jingquan Han[16] | circ-BANP | Up      | LC          | 28/31      | 2.54(0.38-5.68) | 60                |
| Liang Zong[9]     | has_circRNA_102231 | Up     | LC          | 29/28      | 1.04(0.36-2.97) | 60                |
| Mantang Qiu[17]   | circPRKCI | Up      | LAC         | 55/34      | 1.98(1.15-3.58) | 90                |
| Yuanshan Yao[18]  | has_circ_0001946 | Up     | LAC         | 38/34      | 1.70(0.8-3.62)  | 60                |
| Bai-Quan Qiu[19]  | circ-FGFR3 | Up     | NSCLC       | 34/29      | 2.53(1.16-5.48) | 80                |
| Liuxin Wang[20]   | circ-VANGL1 | Up     | NSCLC       | 49/46      | 1.66(0.82-3.37) | 60                |
| Qi Huang[21]      | circ-ATXN7 | Up      | NSCLC       | 45/12      | 1.09(0.48-2.45) | 42                |
| Guohua Liu[22]    | circ-FOXM1 | Up      | NSCLC       | 44/36      | 2.05(1.24-3.37) | 60                |
| Jingchun An[23]   | has_circ_0003645 | Up     | NSCLC       | 32/27      | 2.67(1.48-4.81) | 60                |
| Wei Han[24]       | circ-RAD23B | Up     | NSCLC       | 20/20      | 1.91(0.70-5.18) | 60                |
| Si Qin[25]        | circ-PVT1  | Up      | NSCLC       | 43/47      | 1.68(0.65-4.31) | 60                |
| You Zhou[26]      | hsa_circ_0004015 | Up     | NSCLC       | 16/19      | 1.57(0.37-5.26) | 60                |
| B. YAN[27]        | ciRS-7     | Up      | NSCLC       | NG         | 2.03(1.35-3.06) | 100               |
| Qinguang Zou[28]  | has_circ_0067934 | Up     | NSCLC       | 41/38      | 2.68(1.89-4.00) | 80                |
| Yi Qi[29]         | hsa_circ_0007534 | Up     | NSCLC       | 56/42      | 2.10(1.29-3.42) | 60                |
| Fucheng Zhao[30]  | circ-FADS2 | Up      | NSCLC       | 22/21      | 2.77(0.97-7.93) | 60                |
| Yongsheng Li[31]  | has_circ_0016760 | Up     | NSCLC       | 45/38      | 2.24(1.36-3.69) | 60                |
| Name                  | RNA Name      | Change | Tissue | Tissue Code | p-Value | Fold Change | S |
|-----------------------|---------------|--------|--------|-------------|---------|-------------|---|
| Wei Liu[32]           | hsa_circRNA_103809 | Up     | NSCLC  | 44          | 1.29    | 1.29(0.43,3.86) | 80 |
| Chongyu Su[33]        | ciRS-7        | Up     | NSCLC  | 77          | 2.14    | 2.14(1.44,3.20) | 60 |
| J. WANG[34]           | has_circ_0067934 | Up     | NSCLC  | 79          | 3.77    | 3.77(1.50,6.67) | 60 |
| Danhua Qu[35]         | hsa_circ_0020123 | Up     | NSCLC  | 40          | 1.45    | 1.45(0.43,4.79) | 80 |
| Xiaofei Zhang[36]     | ciRS-7        | Up     | NSCLC  | 41          | 3.58    | 3.58(1.69,4.83) | 80 |
| Jingru Wan[37]        | has_circ_0020123 | Up     | NSCLC  | 28          | 2.50    | 2.50(1.35,4.64) | 60 |
| X.-Y. Li[38]          | hsa_circ_000984 | Up     | NSCLC  | 80          | 3.33    | 3.33(1.26,4.45) | 60 |
| Lingchi Ding[39]      | has_circ_001569 | Up     | NSCLC  | 29          | 2.17    | 2.17(1.11,4.26) | 60 |
| Xiuyuan Chen[40]      | circ-HIPK3    | Up     | NSCLC  | 25          | 2.27    | 2.27(0.76,6.85) | 60 |
| Liu Yang[41]          | hsa_circ_0046264 | Down   | LC     | 55          | 0.53    | 0.53(0.27,1.03) | 20 |
| Daishi Chen[42]       | hsa_circ_100395 | Down   | LC     | 35          | 0.44    | 0.44(0.20,1.02) | 150|
| Yuanshan Yao[43]      | has_circ_0006427 | Down   | LAC    | 54          | 0.44    | 0.44(0.21,0.93) | 60 |
| Binbin Zhang[44]      | circ-MTO1     | Down   | LAC    | 31          | 0.57    | 0.57(0.15,2.21) | 100|
| Tongmiao Liu[45]      | hsa_circ_0001649 | Down   | NSCLC  | 22          | 0.41    | 0.41(0.22,0.77) | 60 |

Note: NSCLC, non-small cell lung cancer; LC, lung cancer; LAC, lung adenocarcinoma.
Figure 2
The clinical application of circRNAs in lung cancer. (A) The ability of circRNAs to differentiate patients with lung cancer from normal people was calculated from the Summary receiver operating characteristic (SROC) curve. (B) Fagan's nomogram was shown to estimate the clinical utility of overall circRNAs to differentiate patients with lung cancer from normal people. (C) Likelihood ratio diagram showed the clinical diagnosis value of circRNAs in lung cancer.

Figure 3
Forest plot by subgroup analysis of diagnostic value in the application of circRNAs in lung cancer. (A) Upregulated circRNAs; (B) Downregulated circRNAs.

Figure 4
Forest plot of overall survival for prognosis of circRNAs in lung cancer. (A) Upregulated circRNAs; (B) Downregulated circRNAs.

Supplementary Files
This is a list of supplementary files associated with this preprint. Click to download.

- SupplementaryFile.rar